Could Opdivo be a New Standard in Esophageal Cancer Therapy?

In a large-scale research study published today in The New England Journal of Medicine (NEJM), Dr. David Ilson reported on the potential of Opdivo (adjuvant nivolumab) as a treatment for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.